Paul Stoffels, Galapagos CEO (Andrew Harnik/AP Images)

Gala­pa­gos sends some em­ploy­ees — and a re­search unit — off to drug dis­cov­ery CRO as part of re­org

Paul Stof­fels has made it clear that he views cut­ting jobs at Gala­pa­gos as dif­fi­cult but nec­es­sary — but he’s get­ting cre­ative about it.

Gala­pa­gos, head­quar­tered in Meche­len, Bel­gium, has struck an arrange­ment with French con­tract re­search or­ga­ni­za­tion No­vAl­iX to trans­fer its drug dis­cov­ery and re­search ac­tiv­i­ties. While No­vAl­iX is based in Stras­bourg, it will take over run­ning the site that Gala­pa­gos ran in Ro­mainville, France.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA